NASDAQ:SYNH - Syneos Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $75.08
  • Forecasted Upside: 4.26 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$72.01
▲ +0.34 (0.47%)
1 month | 3 months | 12 months
Get New Syneos Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYNH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYNH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$75.08
▲ +4.26% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Syneos Health in the last 3 months. The average price target is $75.08, with a high forecast of $87.00 and a low forecast of $52.00. The average price target represents a 4.26% upside from the last price of $72.01.
Buy
The current consensus among 11 polled investment analysts is to buy stock in Syneos Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021BarclaysInitiated CoverageEqual Weight$84.00Medium
i
2/22/2021MizuhoBoost Price TargetBuy$72.00 ➝ $87.00Medium
i
2/19/2021CitigroupBoost Price Target$80.00 ➝ $85.00Low
i
12/9/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$75.00 ➝ $80.00Low
i
12/9/2020JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 ➝ $85.00Low
i
12/9/2020Smith Barney CitigroupBoost Price Target$75.00 ➝ $80.00Low
i
12/9/2020MizuhoBoost Price TargetPositive ➝ Buy$65.00 ➝ $72.00Low
i
12/7/2020Credit Suisse GroupBoost Price TargetOutperform$72.00 ➝ $75.00Medium
i
10/6/2020MizuhoUpgradeNeutral ➝ Buy$63.00 ➝ $65.00Low
i
10/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$69.00 ➝ $75.00High
i
8/12/2020Truist FinancialBoost Price TargetBuy$74.00 ➝ $80.00Medium
i
8/7/2020CitigroupBoost Price TargetBuy$70.00 ➝ $75.00Low
i
8/7/2020MizuhoBoost Price TargetNeutral$50.00 ➝ $63.00Low
i
7/16/2020SunTrust BanksBoost Price TargetBuy$66.00 ➝ $74.00Low
i
5/1/2020SunTrust BanksBoost Price TargetBuy$56.00 ➝ $66.00Medium
i
4/30/2020CfraBoost Price TargetBuy$55.00 ➝ $61.00Medium
i
4/28/2020UBS GroupLower Price TargetNeutral$74.00 ➝ $58.00High
i
4/9/2020CitigroupLower Price TargetBuy$85.00 ➝ $65.00High
i
4/3/2020MizuhoLower Price TargetNeutral$56.00 ➝ $42.00Medium
i
4/2/2020Credit Suisse GroupLower Price TargetOutperform$72.00 ➝ $62.00High
i
Rating by Erin Wright at Credit Suisse Group AG
3/30/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$79.00 ➝ $45.00High
i
3/26/2020BarclaysLower Price TargetEqual Weight$67.00 ➝ $61.00Medium
i
3/23/2020Jefferies Financial GroupLower Price TargetBuy$80.00 ➝ $52.00Medium
i
Rating by David Windley at Jefferies Financial Group Inc.
3/17/2020SunTrust BanksLower Price TargetBuy$80.00 ➝ $58.00Low
i
2/23/2020BarclaysReiterated RatingHold$67.00High
i
2/21/2020Credit Suisse GroupBoost Price TargetOutperform$68.00 ➝ $72.00Low
i
Rating by Erin Wright at Credit Suisse Group AG
2/21/2020Robert W. BairdBoost Price TargetOutperform$74.00 ➝ $82.00Low
i
2/21/2020UBS GroupBoost Price TargetNeutral$62.00 ➝ $74.00Low
i
2/21/2020MizuhoBoost Price TargetNeutral$52.00 ➝ $67.00Low
i
1/21/2020Credit Suisse GroupReiterated RatingBuy$68.00Low
i
Rating by Erin Wright at Credit Suisse Group AG
1/16/2020Robert W. BairdBoost Price TargetOutperform$62.00 ➝ $74.00Medium
i
1/16/2020KeyCorpBoost Price TargetOverweight$65.00 ➝ $71.00Medium
i
1/6/2020CitigroupInitiated CoverageBuy$75.00Low
i
9/23/2019Jefferies Financial GroupBoost Price TargetBuy$62.00 ➝ $65.00Low
i
9/3/2019KeyCorpBoost Price TargetOverweight$63.00 ➝ $65.00Low
i
8/29/2019UBS GroupBoost Price TargetNeutral$53.50 ➝ $57.00Low
i
Rating by Daniel Brennan at UBS Group AG
8/23/2019Credit Suisse GroupBoost Price TargetOutperform$56.00 ➝ $58.00High
i
8/8/2019KeyCorpBoost Price TargetOverweight$59.00 ➝ $63.00Low
i
8/7/2019SunTrust BanksBoost Price TargetBuy$68.00Low
i
4/17/2019BarclaysReiterated RatingHold$48.00High
i
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
i
3/19/2019UBS GroupDowngradeBuy ➝ Neutral$55.00Low
i
Rating by Daniel Brennan at UBS Group AG
3/19/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$49.00 ➝ $51.00Low
i
3/19/2019William BlairReiterated RatingOutperformMedium
i
Rating by J. Kreger at William Blair
1/8/2019Robert W. BairdSet Price TargetBuy$60.00Low
i
Rating by Eric Coldwell at Robert W. Baird
1/3/2019BarclaysLower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $45.00Low
i
12/19/2018SunTrust BanksLower Price TargetBuy$55.00Low
i
10/19/2018William BlairUpgradeMarket Perform ➝ OutperformLow
i
Rating by J. Kreger at William Blair
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$60.00Low
i
10/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$58.00High
i
8/10/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$54.00 ➝ $59.00Low
i
8/6/2018MizuhoReiterated RatingHold$51.00High
i
8/3/2018SunTrust BanksReiterated RatingBuy$60.00Low
i
8/3/2018BarclaysReiterated RatingEqual Weight ➝ Hold$43.00 ➝ $51.00Medium
i
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$50.00Low
i
Rating by J. Twizell at Mitsubishi UFJ Financial Group
3/1/2018BarclaysReiterated RatingEqual Weight ➝ Equal Weight$40.00 ➝ $43.00Low
i
3/1/2018SunTrust BanksBoost Price TargetBuy$55.00Low
i
2/26/2018KeyCorpReiterated RatingOverweight ➝ Overweight$50.00 ➝ $46.00Low
i
2/23/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
i
2/22/2018Robert W. BairdSet Price TargetBuy$50.00High
i
Rating by Eric Coldwell at Robert W. Baird
1/4/2018Credit Suisse GroupReiterated RatingBuy$52.00Medium
i
1/4/2018KeyCorpReiterated RatingBuy$50.00Medium
i
12/11/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$40.00High
i
12/1/2017SunTrust BanksLower Price TargetBuy$50.00Medium
i
12/1/2017MizuhoSet Price TargetNeutral ➝ Neutral$57.00 ➝ $41.00Medium
i
Rating by Ann Hynes at Mizuho
11/16/2017Robert W. BairdSet Price TargetBuy$46.00N/A
i
Rating by Eric Coldwell at Robert W. Baird
11/14/2017Credit Suisse GroupLower Price TargetOutperform$68.00 ➝ $54.00N/A
i
11/13/2017KeyCorpReiterated RatingOverweight ➝ Market Perform$68.00 ➝ $46.00N/A
i
11/10/2017Jefferies Financial GroupReiterated RatingBuy$55.00N/A
i
11/10/2017Robert W. BairdDowngradeOutperform$67.00 ➝ $46.00N/A
i
10/11/2017Credit Suisse GroupInitiated CoverageOutperform$68.00N/A
i
10/9/2017Jefferies Financial GroupUpgradeHold ➝ Buy$62.50 ➝ $69.00N/A
i
10/9/2017Robert W. BairdReiterated RatingBuy$67.00N/A
i
9/21/2017MizuhoInitiated CoverageNeutral$57.00Low
i
8/7/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$65.00Low
i
7/30/2017Jefferies Financial GroupReiterated RatingHold$62.50Low
i
6/29/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$62.00 ➝ $64.00High
i
6/20/2017William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by J. Kreger at William Blair
6/16/2017Jefferies Financial GroupReiterated RatingBuy$62.00Low
i
6/5/2017KeyCorpUpgradeSector Weight ➝ Overweight$68.00Low
i
5/31/2017SunTrust BanksUpgradeHold ➝ Buy$48.00 ➝ $67.00Medium
i
5/11/2017Jefferies Financial GroupReiterated RatingBuyMedium
i
5/11/2017Robert W. BairdUpgradeNeutral ➝ Outperform$46.00 ➝ $66.00Medium
i
5/3/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
i
4/21/2017Jefferies Financial GroupReiterated RatingBuy$51.00Low
i
3/20/2017SunTrust BanksDowngradeBuy ➝ Hold$48.00Medium
i
3/1/2017William BlairReiterated RatingOutperformN/A
i
3/1/2017The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$51.00N/A
i
2/28/2017Jefferies Financial GroupReiterated RatingBuy$59.00 ➝ $51.00N/A
i
1/24/2017Jefferies Financial GroupBoost Price TargetBuy$56.00 ➝ $59.00N/A
i
12/19/2016First AnalysisInitiated CoverageEqual ➝ Equal Weight$59.00N/A
i
11/1/2016Jefferies Financial GroupReiterated RatingBuy$56.00N/A
i
Rating by David Windley at Jefferies Financial Group Inc.
9/8/2016The Goldman Sachs GroupReiterated RatingConviction-Buy$82.00N/A
i
8/17/2016Jefferies Financial GroupLower Price TargetBuy$56.00 ➝ $55.00N/A
i
Rating by David Windley at Jefferies Financial Group Inc.
8/12/2016The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$60.00 ➝ $62.00N/A
i
6/20/2016Credit Suisse GroupInitiated CoverageOutperform$51.00N/A
i
6/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by David Windley at Jefferies Financial Group Inc.
5/22/2016KeyCorpReiterated RatingHoldN/A
i
Rating by Donald Hooker at KeyCorp
5/3/2016Robert W. BairdDowngradeOutperform ➝ Neutral$55.00 ➝ $51.00N/A
i
Rating by Eric Coldwell at Robert W. Baird
4/19/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Eric Coldwell at Robert W. Baird
4/18/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by David Windley at Jefferies Financial Group Inc.
4/18/2016Avondale PartnersBoost Price TargetMarket Perform$39.00 ➝ $47.00N/A
i
3/24/2016JPMorgan Chase & Co.Initiated CoverageOverweight$47.00N/A
i
(Data available from 3/5/2016 forward)
Syneos Health logo
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline; and a partnership with VBI Vaccines Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $72.01
$69.53
$72.92

50 Day Range

MA: $76.46
$71.67
$80.76

52 Week Range

Now: $72.01
$30.02
$81.35

Volume

1,435,530 shs

Average Volume

893,394 shs

Market Capitalization

$7.51 billion

P/E Ratio

39.57

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Syneos Health?

The following equities research analysts have issued reports on Syneos Health in the last year: Barclays PLC, Cfra, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Smith Barney Citigroup, SunTrust Banks, Inc., The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for SYNH.

What is the current price target for Syneos Health?

13 Wall Street analysts have set twelve-month price targets for Syneos Health in the last year. Their average twelve-month price target is $75.08, suggesting a possible upside of 4.3%. Mizuho has the highest price target set, predicting SYNH will reach $87.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $52.00 for Syneos Health in the next year.
View the latest price targets for SYNH.

What is the current consensus analyst rating for Syneos Health?

Syneos Health currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYNH will outperform the market and that investors should add to their positions of Syneos Health.
View the latest ratings for SYNH.

What other companies compete with Syneos Health?

How do I contact Syneos Health's investor relations team?

Syneos Health's physical mailing address is 1030 Sync Street, Morrisville NC, 27560. The company's listed phone number is 919-876-9300 and its investor relations email address is [email protected] The official website for Syneos Health is www.syneoshealth.com.